Hypertensionin-MAU-tionNCT01078584
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients
An observational study of Hypertension, run by Abbott at 568 sites in Canada.
Trial summary
The in-MAU-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching CHEP (Canadian Hypertension Education Program) defined blood pressure targets. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- How many people
- 7,993 participants
- Where
- 568 sitesCanada
- Study dates
- Dec 2008to Sep 2011
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Primary care clinics
Who may be able to join
- Adults capable of providing consent and who have uncontrolled hypertension
- Participants were either treatment-naïve or had uncontrolled hypertension on their existing antihypertensive medication.
Who cannot join
- Participants were excluded from participation in the study if they had been taking trandolapril (Mavik®), alone or in combination, for more than 1 month prior to enrollment.
Trial locations and contacts
568 sites in 1 country.
300 sites in 1 country
Canada300 sites
Site Reference ID/Investigator# 37846
100 Mile House, British Columbia, V0K 2E0
Site Reference ID/Investigator# 30893
Abbotsford British Columbia, British Columbia, V2S 6R6
Site Reference ID/Investigator# 37728
Abbotsford British Columbia, British Columbia, V2T 3S4
Site Reference ID/Investigator# 42367
Ajax, Ontario, L1S 7K8
Site Reference ID/Investigator# 31375
Aldergrove, British Columbia, V4W 3L6
Site Reference ID/Investigator# 31267
Alma, Quebec, G8E 2K2
Site Reference ID/Investigator# 37942
Alma, Quebec, G8E 2K2
Site Reference ID/Investigator# 42464
Ameherstburg, Ontario, N9V 0B4
Site Reference ID/Investigator# 37885
Amherstview, Ontario, K7N 1S3
Site Reference ID/Investigator# 30885
Anjou, Quebec, H1M 3M4
Site Reference ID/Investigator# 42409
Aurora, Ontario, L4G 7Y3
Site Reference ID/Investigator# 42449
Aurora, Ontario, L4G 7Y3
Site Reference ID/Investigator# 30943
Aurora, Ontario, L4G 7Z9
Site Reference ID/Investigator# 31331
Aylmer, Quebec, N5H 1K9
Site Reference ID/Investigator# 30963
Barrie, Ontario, L4N 6M2
Site Reference ID/Investigator# 31304
Beauceville, Quebec, G5X 1J9
Site Reference ID/Investigator# 30954
Belleville, Ontario, K8N 5G8
Site Reference ID/Investigator# 30879
Belleville, Ontario, K8P 5E2
Site Reference ID/Investigator# 42378
Bolton, Ontario, L7E 4C8
Site Reference ID/Investigator# 30888
Bowmanville, Ontario, L1C 1P3
Site Reference ID/Investigator# 30947
Bowmanville, Ontario, L1C 1P6
Site Reference ID/Investigator# 31286
Bradford, Ontario, L3Z 2B6
Site Reference ID/Investigator# 32192
Bradford, Ontario, L3Z 2B8
Site Reference ID/Investigator# 37911
Brampton, Ontario, L6R 3J5
Site Reference ID/Investigator# 37932
Brampton, Ontario, L6T 3R5
Site Reference ID/Investigator# 30882
Brampton, Ontario, L6X 5E9
Site Reference ID/Investigator# 37929
Brampton, Ontario, L7A 3E5
Site Reference ID/Investigator# 32227
Brandon, Manitoba, R7A 0B9
Site Reference ID/Investigator# 37768
Brantford, Ontario, N3T 5Z8
Site Reference ID/Investigator# 31314
Bridgewater, Nova Scotia, B4V 2V6
Site Reference ID/Investigator# 31276
Bridgewater, Nova Scotia, B4V 3N2
Site Reference ID/Investigator# 31369
Bromont, Quebec, J2L 2C3
Site Reference ID/Investigator# 30903
Brossard, Quebec, J4Z 3G9
Site Reference ID/Investigator# 37934
Burlington, Ontario, L7L 0B7
Site Reference ID/Investigator# 32173
Burlington, Ontario, L7M 4Y1
Site Reference ID/Investigator# 32210
Burlington, Ontario, L7R 1E2
Site Reference ID/Investigator# 37919
Burlington, Ontario, L7R 2H3
Site Reference ID/Investigator# 31359
Burlington, Ontario, L7R 2H7
Site Reference ID/Investigator# 37923
Burlington, Ontario, L7R 2H7
Site Reference ID/Investigator# 37845
Burlington, Ontario, L7R 4H9
Site Reference ID/Investigator# 30870
Burnaby, British Columbia, V5C 5R4
Site Reference ID/Investigator# 30964
Burnaby, British Columbia, V5E 1E7
Site Reference ID/Investigator# 31261
Burnaby, British Columbia, V5H 2A9
Site Reference ID/Investigator# 30946
Burnaby, British Columbia, V5H 4J2
Site Reference ID/Investigator# 30927
Burnaby, British Columbia, V5H 4M4
Site Reference ID/Investigator# 32207
Calgary, Alberta, T1Y 6H6
Site Reference ID/Investigator# 10283
Calgary, Alberta, T2E 2S9
Site Reference ID/Investigator# 32168
Calgary, Alberta, T2J 3N8
Site Reference ID/Investigator# 32147
Calgary, Alberta, T2M 0H5
Site Reference ID/Investigator# 42438
Calgary, Alberta, T2V 0M3
Site Reference ID/Investigator# 32157
Calgary, Alberta, T2V 1K2
Site Reference ID/Investigator# 37940
Calgary, Alberta, T2X 1P1
Site Reference ID/Investigator# 32199
Calgary, Alberta, T2X 3X7
Site Reference ID/Investigator# 32144
Calgary, Alberta, T3C 3P1
Site Reference ID/Investigator# 32169
Calgary, Alberta, T3E 5R7
Site Reference ID/Investigator# 32145
Charlottetown, Prince Edward Island, C1A 1L2
Site Reference ID/Investigator# 32195
Charlottetown, Prince Edward Island, C1A 2M5
Site Reference ID/Investigator# 32221
Charlottetown, Prince Edward Island, C1A 6Y1
Site Reference ID/Investigator# 42335
Chicoutimi, Quebec, G7H 1G8
Site Reference ID/Investigator# 31260
Chicoutimi, Quebec, G7J 2V1
Site Reference ID/Investigator# 31398
Clemont, Quebec, G4A 1G3
Site Reference ID/Investigator# 30911
Clermont, Quebec, G4A 1G3
Site Reference ID/Investigator# 31323
Clermont, Quebec, G4A 1G3
Site Reference ID/Investigator# 47571
Collingwood, Ontario, L9Y 1W6
Site Reference ID/Investigator# 30878
Conception Bay South, Newfoundland and Labrador, A1W 3A6
Site Reference ID/Investigator# 42433
Coquitlam, British Columbia, V3B 6J6
Site Reference ID/Investigator# 32213
Coquitlam, British Columbia, V3B 6S2
Site Reference ID/Investigator# 30956
Cornwall, Ontario, K6H 4A2
Site Reference ID/Investigator# 37897
Cornwall, Prince Edward Island, C0A 1H0
Site Reference ID/Investigator# 30969
Corunna, Ontario, N0N 1G0
Site Reference ID/Investigator# 30928
Cote-St-Luc, Quebec, H3W 1Z7
Site Reference ID/Investigator# 37782
Craik, Saskatchewan, S0G 0V0
Site Reference ID/Investigator# 31264
Dartmouth, Nova Scotia, B2W 3E5
Site Reference ID/Investigator# 31321
Dartmouth, Nova Scotia, B2W 3E5
Site Reference ID/Investigator# 30961
Dashwood, Ontario, N0M 1N0
Site Reference ID/Investigator# 32166
Delta, British Columbia, V4C 6R2
Site Reference ID/Investigator# 31288
Delta, British Columbia, V4C 6R4
Site Reference ID/Investigator# 42404
Delta, British Columbia, V4C 6R4
Site Reference ID/Investigator# 37922
Delta, British Columbia, V4E 2A6
Site Reference ID/Investigator# 30926
Delta, British Columbia, V4K 2K5
Site Reference ID/Investigator# 32209
Dieppe, New Brunswick, E1A 1N5
Site Reference ID/Investigator# 37850
Dolbeau-Mistassini, Ontario, G8L 5J8
Site Reference ID/Investigator# 42386
Dolbeau-Mistassini, Quebec, G8L 1H1
Site Reference ID/Investigator# 31281
Dolbeau-Mistassini, Quebec, G8L 5J8
Site Reference ID/Investigator# 42389
Durham, Ontario, N0G 1R0
Site Reference ID/Investigator# 42385
East York, Ontario, M4B 2S7
Site Reference ID/Investigator# 42397
East York, Ontario, M4C 5M1
Site Reference ID/Investigator# 42400
East York, Ontario, M4C 5M1
Site Reference ID/Investigator# 42423
East York, Ontario, M4C 5M1
Site Reference ID/Investigator# 30930
East York, Ontario, M4C 5T2
Site Reference ID/Investigator# 31363
East York, Ontario, M4K 3V9
Site Reference ID/Investigator# 42391
Edmonton, Alberta, T5C 3H7
Site Reference ID/Investigator# 32146
Edmonton, Alberta, T5K 0N8
Site Reference ID/Investigator# 32165
Edmonton, Alberta, T5T 2K6
Site Reference ID/Investigator# 32197
Edmonton, Alberta, T5T 2K6
Site Reference ID/Investigator# 32126
Edmonton, Alberta, T5T 4J5
Site Reference ID/Investigator# 37892
Edmonton, Alberta, T5T 5L4
Site Reference ID/Investigator# 32178
Edmonton, Alberta, T5T 5Y1
Site Reference ID/Investigator# 42406
Edmonton, Alberta, T5W 4W1
Site Reference ID/Investigator# 32160
Edmonton, Alberta, T5X 3N5
Site Reference ID/Investigator# 32200
Edmonton, Alberta, T5X 3N5
Site Reference ID/Investigator# 32149
Edmonton, Alberta, T6A 0A5
Site Reference ID/Investigator# 32156
Edmonton, Alberta, T6B 0P2
Site Reference ID/Investigator# 32216
Edmonton, Alberta, T6H 5B4
Site Reference ID/Investigator# 32206
Edmonton, Alberta, T6L 6N3
Site Reference ID/Investigator# 42342
Elmvale, Ontario, L0L 1P0
Site Reference ID/Investigator# 32873
Etobicoke, Ontario, M8V 3X8
Site Reference ID/Investigator# 31353
Etobicoke, Ontario, M8W 3W2
Site Reference ID/Investigator# 37774
Etobicoke, Ontario, M8X 1E2
Site Reference ID/Investigator# 32871
Etobicoke, Ontario, M9B 3Z9
Site Reference ID/Investigator# 32870
Etobicoke, Ontario, M9V 5G4
Site Reference ID/Investigator# 32872
Etobicoke, Ontario, M9V 5G4
Site Reference ID/Investigator# 32880
Fonthill, Ontario, L0S 1E0
Site Reference ID/Investigator# 30873
Fort Erie, Ontario, L2A 1Z3
Site Reference ID/Investigator# 31310
Fort Erie, Ontario, L2A 1Z3
Site Reference ID/Investigator# 31356
Fort Erie, Ontario, L2A 6E2
Site Reference ID/Investigator# 32182
Gatineau, Quebec, J8X 4B6
Site Reference ID/Investigator# 37937
Gatineau, Quebec, J8X 4B7
Site Reference ID/Investigator# 37843
Gatineau, Quebec, J8Y 1W7
Site Reference ID/Investigator# 32910
Gatineau, Quebec, J8Y 3B5
Site Reference ID/Investigator# 32911
Gatineau, Quebec, J8Y 6S9
Site Reference ID/Investigator# 37941
Gatineau, Quebec, J9J 2M9
Site Reference ID/Investigator# 31367
Georgetown, Ontario, L7G 5E9
Site Reference ID/Investigator# 31381
Georgetown, Ontario, L7G 5G1
Site Reference ID/Investigator# 30933
Gimli, Manitoba, R0C 1B0
Site Reference ID/Investigator# 31393
Grand-Mère, Quebec, G9T 2J1
Site Reference ID/Investigator# 31379
Grand-Mère, Quebec, G9T 3S7
Site Reference ID/Investigator# 37852
Grand-Mère, Quebec, G9T 3S7
Site Reference ID/Investigator# 32141
Grand-Mère, Quebec, G9T 4T8
Site Reference ID/Investigator# 47572
Grande-Allee, Quebec, J7G 1W6
Site Reference ID/Investigator# 37672
Greater Sudbury, Ontario, L5B 6C3
Site Reference ID/Investigator# 37674
Greater Sudbury, Ontario, P3A 1Y8
Site Reference ID/Investigator# 31271
Greater Sudbury, Ontario, P3E 1A9
Site Reference ID/Investigator# 37784
Greater Sudbury, Ontario, P3E 1B8
Site Reference ID/Investigator# 32529
Greater Sudbury, Ontario, P3E 3C6
Site Reference ID/Investigator# 30904
Greenfield Park, Quebec, J4V 2G8
Site Reference ID/Investigator# 30965
Grimsby, Ontario, L3M 1P1
Site Reference ID/Investigator# 31285
Grimsby, Ontario, L3M 1P3
Site Reference ID/Investigator# 42347
Guelph, Ontario, N1E 6L9
Site Reference ID/Investigator# 42462
Guelph, Ontario, N1H 5J1
Site Reference ID/Investigator# 31327
Halifax, Nova Scotia, B3H 2Y1
Site Reference ID/Investigator# 31282
Hamilton, Ontario, L8H 4R6
Site Reference ID/Investigator# 32223
Hamilton, Ontario, L8J 0B6
Site Reference ID/Investigator# 42440
Hamilton, Ontario, L8J 2N5
Site Reference ID/Investigator# 32214
Hamilton, Ontario, L8K 3P3
Site Reference ID/Investigator# 30924
Hamilton, Ontario, L8L 5G8
Site Reference ID/Investigator# 31348
Hamilton, Ontario, L8L 5G8
Site Reference ID/Investigator# 30940
Hamilton, Ontario, L8S 1C5
Site Reference ID/Investigator# 37907
Hamilton, Ontario, L8S 1E7
Site Reference ID/Investigator# 31389
Hamilton, Ontario, L9A 2G7
Site Reference ID/Investigator# 31275
Hamilton, Ontario, L9A 5H4
Site Reference ID/Investigator# 32965
Hawkesbury, Ontario, K6A 2R2
Site Reference ID/Investigator# 31373
Hawkesbury, Ontario, K6A 3B2
Site Reference ID/Investigator# 32966
Hébertville, Quebec, G8B 1N3
Site Reference ID/Investigator# 32167
Hull, Quebec, J8Y 6S9
Site Reference ID/Investigator# 33002
Jarvis, Ontario, N0A 1J0
Site Reference ID/Investigator# 30876
Jordan Station, Ontario, L0R 1S0
Site Reference ID/Investigator# 37666
Kamloops, British Columbia, V1S 1M9
Site Reference ID/Investigator# 30929
Kamloops, British Columbia, V2B 3G9
Site Reference ID/Investigator# 32203
Kamloops, British Columbia, V2C 5Y2
Site Reference ID/Investigator# 37882
Kamloops, British Columbia, V3B 3G2
Site Reference ID/Investigator# 42365
Kelowna, British Columbia, V1V 1A1
Site Reference ID/Investigator# 33018
Kelowna, British Columbia, V1X 7N6
Site Reference ID/Investigator# 30915
Kelowna, British Columbia, V1Y 8J8
Site Reference ID/Investigator# 33019
Kensington, Prince Edward Island, C0B 1M0
Site Reference ID/Investigator# 37781
Kentville, Nova Scotia, B4N 1M6
Site Reference ID/Investigator# 32611
Keswick, Ontario, L4P 0A9
Site Reference ID/Investigator# 33020
Keswick, Ontario, L4P 2C7
Site Reference ID/Investigator# 31386
Kirkfield, Ontario, K0M 2B0
Site Reference ID/Investigator# 31298
Kirkland, Quebec, H9J 2W2
Site Reference ID/Investigator# 42443
Kitchener, Ontario, N2G 1E3
Site Reference ID/Investigator# 30895
Kitchener, Ontario, N2G 4V4
Site Reference ID/Investigator# 37783
Kitchener, Ontario, N2G 4V5
Site Reference ID/Investigator# 37906
Kitchener, Ontario, N2M 5N6
Site Reference ID/Investigator# 42467
Kitchener, Ontario, N2N 2A8
Site Reference ID/Investigator# 32189
L'Anse-Saint-Jean, Quebec, G0V 1J0
Site Reference ID/Investigator# 42344
La Baie, Quebec, G7B 0A3
Site Reference ID/Investigator# 42343
La Malbaie, Quebec, G5A 1W7
Site Reference ID/Investigator# 32174
La Salle, Ontario, N9J 2C1
Site Reference ID/Investigator# 37910
La Salle, Ontario, N9J 2C1
Site Reference ID/Investigator# 42377
Lachenaie, Quebec, J6V 1S8
Site Reference ID/Investigator# 30877
Lachute, Quebec, J8H 1S4
Site Reference ID/Investigator# 33043
Langley, British Columbia, V3A 4G5
Site Reference ID/Investigator# 31347
LaSalle, Ontario, H8N 1X9
Site Reference ID/Investigator# 30968
LaSalle, Quebec, H8N 1T5
Site Reference ID/Investigator# 30918
LaSalle, Quebec, H8N 1X9
Site Reference ID/Investigator# 33042
LaSalle, Quebec, N9J 2C1
Site Reference ID/Investigator# 33046
Laval, Quebec, H7K 2J4
Site Reference ID/Investigator# 31397
Laval, Quebec, H7L 3A2
Site Reference ID/Investigator# 37855
Laval, Quebec, H7P 5L3
Site Reference ID/Investigator# 37856
Laval, Quebec, H7P 5L3
Site Reference ID/Investigator# 42437
Laval, Quebec, H7P 5L3
Site Reference ID/Investigator# 30871
Laval, Quebec, H7V 2W2
Site Reference ID/Investigator# 42402
Laval, Quebec, H7X 3S5
Site Reference ID/Investigator# 31362
Lévis, Quebec, G0R 3E0
Site Reference ID/Investigator# 33062
Lévis, Quebec, G6V 8V3
Site Reference ID/Investigator# 32220
Lindsay, Ontario, K9V 5N7
Site Reference ID/Investigator# 42348
Lindsay, Ontario, K9V 6C5
Site Reference ID/Investigator# 32196
London, Ontario, N5V 2E3
Site Reference ID/Investigator# 30900
London, Ontario, N5Y 3H9
Site Reference ID/Investigator# 33070
London, Ontario, N6A 5G9
Site Reference ID/Investigator# 31333
London, Ontario, N6C 4Y7
Site Reference ID/Investigator# 32148
London, Ontario, N6E 3B9
Site Reference ID/Investigator# 31340
London, Ontario, N6J 1Y4
Site Reference ID/Investigator# 31371
Longueuil, Quebec, J4J 3X5
Site Reference ID/Investigator# 33072
Lower Sackville, Nova Scotia, B4C 2N1
Site Reference ID/Investigator# 30894
Lower Sackville, Nova Scotia, B4C 2R3
Site Reference ID/Investigator# 31315
Maple Ridge, British Columbia, V2X 6A4
Site Reference ID/Investigator# 31385
Markham, Ontario, L3P 5T7
Site Reference ID/Investigator# 33091
Markham, Ontario, L3S 1R7
Site Reference ID/Investigator# 33090
Markham, Ontario, L3S 3K9
Site Reference ID/Investigator# 42337
Markham, Ontario, L6B 0P9
Site Reference ID/Investigator# 30957
Marystown, Newfoundland and Labrador, A0E 2M0
Site Reference ID/Investigator# 33094
Marystown, Newfoundland and Labrador, A0E 2M0
Site Reference ID/Investigator# 42461
Middleton, Nova Scotia, B0S 1P0
Site Reference ID/Investigator# 30967
Milton, Ontario, L9T 6R2
Site Reference ID/Investigator# 33104
Mississauga, Ontario, L4T 4E3
Site Reference ID/Investigator# 42398
Mississauga, Ontario, L4X 2Z9
Site Reference ID/Investigator# 33106
Mississauga, Ontario, L4Y 2A6
Site Reference ID/Investigator# 30945
Mississauga, Ontario, L5A 1W4
Site Reference ID/Investigator# 33105
Mississauga, Ontario, L5B 3A8
Site Reference ID/Investigator# 37673
Mississauga, Ontario, L5B 4M4
Site Reference ID/Investigator# 42331
Mississauga, Ontario, L5B 4M4
Site Reference ID/Investigator# 42373
Mississauga, Ontario, L5C 2R9
Site Reference ID/Investigator# 42468
Mississauga, Ontario, L5C 2R9
Site Reference ID/Investigator# 32152
Mississauga, Ontario, L5N 2W7
Site Reference ID/Investigator# 37723
Mississauga, Ontario, L5N 4H4
Site Reference ID/Investigator# 37903
Mississauga, Ontario, L5N 6S3
Site Reference ID/Investigator# 37904
Mississauga, Ontario, L5N 6S3
Site Reference ID/Investigator# 31312
Mississauga, Ontario, L5R 4B8
Site Reference ID/Investigator# 30909
Mistassini, Quebec, G8L 5J8
Site Reference ID/Investigator# 32212
Moncton, New Brunswick, E1C 1X6
Site Reference ID/Investigator# 37851
Montreal, Quebec, H1L 2N9
Site Reference ID/Investigator# 31324
Montreal, Quebec, H1T 1S6
Site Reference ID/Investigator# 31308
Montreal, Quebec, H1T 2M4
Site Reference ID/Investigator# 33115
Montreal, Quebec, H1V 1X4
Site Reference ID/Investigator# 42394
Montreal, Quebec, H1W 1S5
Site Reference ID/Investigator# 30921
Montreal, Quebec, H1X 1R6
Site Reference ID/Investigator# 31390
Montreal, Quebec, H1X 1R6
Site Reference ID/Investigator# 33111
Montreal, Quebec, H1X 1R6
Site Reference ID/Investigator# 33110
Montreal, Quebec, H2N 2H7
Site Reference ID/Investigator# 42395
Montreal, Quebec, H2S 2W1
Site Reference ID/Investigator# 30905
Montreal, Quebec, H3K 1W7
Site Reference ID/Investigator# 33112
Montreal, Quebec, H3L 2E8
Site Reference ID/Investigator# 30950
Montreal, Quebec, H3M 3A9
Site Reference ID/Investigator# 31279
Montreal, Quebec, H3M 3E2
Site Reference ID/Investigator# 31293
Montreal, Quebec, H3M 3E2
Site Reference ID/Investigator# 31294
Montreal, Quebec, H3S 1Z4
Site Reference ID/Investigator# 33114
Montreal, Quebec, H3S 1Z6
Site Reference ID/Investigator# 33116
Montreal, Quebec, H3S 2B2
Site Reference ID/Investigator# 31311
Montreal, Quebec, H3Z 1X5
Site Reference ID/Investigator# 32158
Montreal, Quebec, H4E 2K9
Site Reference ID/Investigator# 32154
Mount Pearl, Newfoundland and Labrador, A1N 5K8
Site Reference ID/Investigator# 33193
Mount Pearl, Newfoundland and Labrador, A1N 5K8
Site Reference ID/Investigator# 42327
Nepean, Ontario, K2G 1W2
Site Reference ID/Investigator# 31364
Nepean, Ontario, K2H 9A5
Site Reference ID/Investigator# 31334
Nepean, Ontario, K2J 3Z6
Site Reference ID/Investigator# 31357
Newboro, Ontario, K0G 1P0
Site Reference ID/Investigator# 42445
Newcastle, Ontario, L1B 1H8
Site Reference ID/Investigator# 37770
Newmarket, Ontario, L3Y 2N1
Site Reference ID/Investigator# 30970
Newmarket, Ontario, L3Y 5G8
Site Reference ID/Investigator# 31388
Newmarket, Ontario, L3Y 5G8
Site Reference ID/Investigator# 37930
Newmarket, Ontario, L3Y 7V1
Site Reference ID/Investigator# 32172
Niagara Falls, Ontario, L2G 6B9
Site Reference ID/Investigator# 33232
North Battleford, Saskatchewan, S9A 0V6
Site Reference ID/Investigator# 33233
North Battleford, Saskatchewan, S9A 0V6
Site Reference ID/Investigator# 31366
North Battleford, Saskatchewan, S9A 3G8
Site Reference ID/Investigator# 31326
North Bay, Ontario, P1B 0A7
Site Reference ID/Investigator# 30913
North Bay, Ontario, P1B 8G1
Site Reference ID/Investigator# 33234
North Vancouver, British Columbia, V7M 2K2
Site Reference ID/Investigator# 30937
North York, Ontario, M2J 2Z1
Site Reference ID/Investigator# 32601
North York, Ontario, M2N 7J5
Site Reference ID/Investigator# 32602
North York, Ontario, M2N 7J5
Site Reference ID/Investigator# 42442
North York, Ontario, M3B 2W7
Site Reference ID/Investigator# 30896
North York, Ontario, M3C 1T2
Site Reference ID/Investigator# 31265
North York, Ontario, M3C 1T2
Site Reference ID/Investigator# 32607
North York, Ontario, M3J 1N2
Site Reference ID/Investigator# 42407
North York, Ontario, M3N 2K1
Site Reference ID/Investigator# 42435
North York, Ontario, M3N 2Z9
Site Reference ID/Investigator# 33235
North York, Ontario, M9N 1X2
Site Reference ID/Investigator# 31350
Oakville, Ontario, L6H 3P1
Site Reference ID/Investigator# 37842
Oakville, Ontario, L6H 3P1
Site Reference ID/Investigator# 30910
Oshawa, Ontario, L1H 1B9
Site Reference ID/Investigator# 30971
Oshawa, Ontario, L1H 1B9
Site Reference ID/Investigator# 42459
Oshawa, Ontario, L1H 1B9
Site Reference ID/Investigator# 42415
Oshawa, Ontario, L1H 1G4
Site Reference ID/Investigator# 32162
Oshawa, Ontario, L1H 7K4
Site Reference ID/Investigator# 33260
Oshawa, Ontario, L1H 7K4
Site Reference ID/Investigator# 42363
Oshawa, Ontario, L1H 7K4
Site Reference ID/Investigator# 32164
Oshawa, Ontario, L1J 2K1
Site Reference ID/Investigator# 32185
Ottawa, Ontario, K1H 1A2
Site Reference ID/Investigator# 37884
Ottawa, Ontario, K1H 1A2
Site Reference ID/Investigator# 32422
Ottawa, Ontario, K1K 4L2
Site Reference ID/Investigator# 33267
Ottawa, Ontario, K1L 8M3
Site Reference ID/Investigator# 42425
Ottawa, Ontario, K1Z 7K8
Site Reference ID/Investigator# 32190
Ottawa, Ontario, K2A 3V5
Site Reference ID/Investigator# 31380
Ottawa, Ontario, K2B 7Z2
Site Reference ID/Investigator# 31287
Ottawa, Ontario, K2C 0C7
Site Reference ID/Investigator# 33266
Ottawa, Ontario, K2C 0C7
Site Reference ID/Investigator# 31301
Ottawa, Ontario, K2G 3Y5
About this study
Official title: A Prospective, Non-interventional, Observational Study To Describe the Effectiveness of Trandolapril (Mavik®) in the Management of Patients Requiring Angiotensin Converting Enzyme Inhibitor Treatment (In-MAU-tion)
The in-MAU-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching CHEP (Canadian Hypertension Education Program) defined blood pressure targets. Additionally, the study assesses change in renal function (microalbuminuria, estimated glomerular filtration rate) in hypertensive participants treated with trandolapril (Mavik®) and examines patient satisfaction with trandolapril (Mavik®) therapy.
Read the detailed description
There are no interventional implications in this study. The study runs under consideration of Canadian Hypertension Education Program guidelines and as per standard practice of care. Data collection is recorded on the appropriate case report forms. The data collected consist of: patient demographics (gender, race, age, weight), blood pressure readings, heart rate, coexisting comorbidities, concomitant chronic medications (generic name and dosage), indication and dose for trandolapril (Mavik®) and patient compliance. Laboratory values (microalbuminuria, estimated glomerular filtration rate) are only collected if the data are available for each patient. For baseline values (study Day 0), any laboratory value recorded within the past year prior to the baseline visit (Visit 1) is recorded, if the value is available. As per Canadian Hypertension Education Program recommendations and as a support and educational measure, patients are provided with (1) educational tools (nutrition guidebooks) and (2) home blood pressure monitoring devices. As per research and development guidelines, blood pressure devices were retrieved at the end of the study. Approximately 8,000 hypertensive participants were enrolled in the study at up to 700 sites across Canada. Sample size estimations were based on the assumption that 67.2% of non-diabetic hypertensive participants (assumed to make up to 69% of the eligible participant population) would reach a blood pressure target of <140/90mm Hg, while 22% of diabetes participants (31% of the eligible population) would meet a blood pressure target of <130/80 mm Hg with trandolapril (Mavik®) therapy.
- Conditions
- Hypertension
- Keywords
- Uncontrolled hypertension, trandolapril
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hypertensive Participants | Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 3 Months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
Measured: 3 months
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 6 Months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
Measured: 6 months
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 12 Months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
Measured: 12 months
Secondary outcomes (11)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 3 Months
Diabetics were considered to be "BP-controlled" if BP <130/80 mm Hg. Diabetics were considered to be "BP-uncontrolled" if BP >/=130/80 mm Hg.
Measured: Baseline, 3 Months
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 6 Months
Diabetics were considered to be "BP-controlled" if BP <130/80 mm Hg. Diabetics were considered to be "BP-uncontrolled" if BP >/=130/80 mm Hg.
Measured: Baseline, 6 Months
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 12 Months
Diabetics were considered to be "BP-controlled" if BP <130/80 mm Hg. Diabetics were considered to be "BP-uncontrolled" if BP >/=130/80 mm Hg.
Measured: Baseline,12 Months
Change From Baseline in Microalbuminuria (MAU) at 3 Months
Measured: Baseline, 3 Months
Change From Baseline in Microalbuminuria (MAU) at 6 Months
Measured: Baseline, 6 Months
Change From Baseline in Microalbuminuria (MAU) at 12 Months
Measured: Baseline, 12 months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 3 Months of Therapy
The 2008 CHEP systolic BP (SBP) target is <140 mm Hg. Where a participant had an SBP less than the target, the participant's SBP was defined as "controlled."
Measured: 3 Months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 6 Months of Therapy
The 2008 CHEP systolic BP (SBP) target is <140 mm Hg. Where a participant had an SBP less than the target, the participant's SBP was defined as "controlled."
Measured: 6 Months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 12 Months of Therapy
The 2008 CHEP systolic BP (SBP) target is <140 mm Hg. Where a participant had an SBP less than the target, the participant's SBP was defined as "controlled."
Measured: 12 Months
Percentage of Participants Reporting Defined Levels of Satisfaction With Current Therapy at Baseline and After 12 Months of Therapy
Satisfaction with therapy at baseline (BL) and 12 months, using a 5-point Likert scale where participants responded to the question "Are you satisfied with your current hypertension therapy?". The range of responses varied from "1 = not at all satisfied" to "5 = extremely satisfied." Responses "2" through "4" were not otherwise defined, but represented increments of more or less satisfaction with current therapy, respectively.
Measured: Day 0 (Baseline), 12 months
Percentage of Participants Reporting Defined Levels of Satisfaction With Current Therapy at Baseline Versus After 12 Months of Therapy
Satisfaction with therapy at baseline (BL) versus 12 months, using a 5-point Likert scale where participants responded to the question "Are you satisfied with your current hypertension therapy?". The range of responses varied from "1 = not at all satisfied" to "5 = extremely satisfied." Responses "2" through "4" were not otherwise defined, but represented increments of more or less satisfaction with current therapy, respectively.
Measured: Day 0 (Baseline), 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2010 (estimated)
- Study startDec 2008
- Primary completionSep 2011
- Study completionSep 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7,993 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abbott
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- McKesson Canada
- Responsible party
- Sponsor
- Investigators
- Linda Assouline, PhD, Study director, Abbott
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01078584
- Sponsor's protocol ID
- P10-665
- Acronym
- in-MAU-tion
- Status last verified
- Oct 2012
- First submitted
- 1 Mar 2010
- Last updated
- 25 Oct 2012
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 25 Oct 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Non-interventional, Observational Study To Describe the Effectiveness of Trandolapril (Mavik®) in the Management of Patients Requiring Angiotensin Converting Enzyme Inhibitor Treatment (In-MAU-tion)
- ClinicalTrials.gov ID
- NCT01078584
- Acronym / sponsor ID
- in-MAU-tion / P10-665
- Conditions
- Hypertension
- Keywords
- Uncontrolled hypertension, trandolapril
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7,993 participants (actual)
- Lead sponsor
- AbbottIndustry (pharma, biotech, devices)
- Collaborators
- McKesson Canada
- Study start
- Dec 2008
- Primary completion
- Sep 2011 (actual)
- Study completion
- Sep 2011 (actual)
- First posted
- 2 Mar 2010 (estimated)
- Results
- Posted 11 Oct 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The in-MAU-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching CHEP (Canadian Hypertension Education Program) defined blood pressure targets. Additionally, the study assesses change in renal function (microalbuminuria, estimated glomerular filtration rate) in hypertensive participants treated with trandolapril (Mavik®) and examines patient satisfaction with trandolapril (Mavik®) therapy.
Detailed description
There are no interventional implications in this study. The study runs under consideration of Canadian Hypertension Education Program guidelines and as per standard practice of care. Data collection is recorded on the appropriate case report forms. The data collected consist of: patient demographics (gender, race, age, weight), blood pressure readings, heart rate, coexisting comorbidities, concomitant chronic medications (generic name and dosage), indication and dose for trandolapril (Mavik®) and patient compliance. Laboratory values (microalbuminuria, estimated glomerular filtration rate) are only collected if the data are available for each patient. For baseline values (study Day 0), any laboratory value recorded within the past year prior to the baseline visit (Visit 1) is recorded, if the value is available. As per Canadian Hypertension Education Program recommendations and as a support and educational measure, patients are provided with (1) educational tools (nutrition guidebooks) and (2) home blood pressure monitoring devices. As per research and development guidelines, blood pressure devices were retrieved at the end of the study. Approximately 8,000 hypertensive participants were enrolled in the study at up to 700 sites across Canada. Sample size estimations were based on the assumption that 67.2% of non-diabetic hypertensive participants (assumed to make up to 69% of the eligible participant population) would reach a blood pressure target of <140/90mm Hg, while 22% of diabetes participants (31% of the eligible population) would meet a blood pressure target of <130/80 mm Hg with trandolapril (Mavik®) therapy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hypertensive Participants | – | –Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Primary care clinics
Key inclusion criteria (2 listed)
- Adults capable of providing consent and who have uncontrolled hypertension
- Participants were either treatment-naïve or had uncontrolled hypertension on their existing antihypertensive medication.
Key exclusion criteria (1 listed)
- Participants were excluded from participation in the study if they had been taking trandolapril (Mavik®), alone or in combination, for more than 1 month prior to enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 3 Months
Time frame: 3 months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 6 Months
Time frame: 6 months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 12 Months
Time frame: 12 months
Blood pressure (BP) targets, as specified in the 2008 CHEP recommendations, were systolic BP (SBP)/diastolic BP (DBP) <140/90 mm Hg for non-diabetic participants, and SBP/DBP <130/80 mm Hg for diabetic participants.
11 secondary outcomes
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 3 Months
Time frame: Baseline, 3 Months
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 6 Months
Time frame: Baseline, 6 Months
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) in Blood Pressure (BP)-Controlled and BP-Uncontrolled Diabetics at 12 Months
Time frame: Baseline,12 Months
Change From Baseline in Microalbuminuria (MAU) at 3 Months
Time frame: Baseline, 3 Months
Change From Baseline in Microalbuminuria (MAU) at 6 Months
Time frame: Baseline, 6 Months
Change From Baseline in Microalbuminuria (MAU) at 12 Months
Time frame: Baseline, 12 months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 3 Months of Therapy
Time frame: 3 Months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 6 Months of Therapy
Time frame: 6 Months
Percentage of Participants With Isolated Systolic Hypertension (ISH) Reaching 2008 CHEP Systolic Blood Pressure (BP) Target After 12 Months of Therapy
Time frame: 12 Months
Percentage of Participants Reporting Defined Levels of Satisfaction With Current Therapy at Baseline and After 12 Months of Therapy
Time frame: Day 0 (Baseline), 12 months
Percentage of Participants Reporting Defined Levels of Satisfaction With Current Therapy at Baseline Versus After 12 Months of Therapy
Time frame: Day 0 (Baseline), 12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Oct 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Linda Assouline, PhD study director
Abbott
568 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Abbott at 568 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 568 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Oct 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 3 Months (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2012.